ESC 365 - Low-dose rivaroxaban during the acute phase of ACS

Back

ESC Premium Access

Low-dose rivaroxaban during the acute phase of ACS - H-REPLACE Trial)

Session: Late Breaking Trials in ACS

Topic: Pharmacotherapy

Speaker: Professor S. Zhou (Changsha, CN)

Event: ESC Congress 2021 - The Digital Experience

Congress Presentation

About the speaker

Professor Shenghua Zhou

The Second Xiangya Hospital of Central South University, Changsha (China)

1 presentation

1 follower

3 more presentations in this session

QUORUM : Quantum Genomics Firibastat (QGC001) or Ramipril after Acute Myocardial Infarction for Prevention of Left Ventricular Dysfunction

Speaker: Professor G. Montalescot (Paris, FR)

Access

Slides

Video

HUYGENS: Evolocumab and changes in plaque composition on OCT

Speaker: Professor S. Nicholls (Melbourne, AU)

Access

Slides

Video

ACCOST-HH: Adrecizumab in cardiogenic shock

Speaker: Doctor M. Karakas (Hamburg, DE)

Access

Slides

Video

Access the full session

Late Breaking Trials in ACS

Speakers: Professor S. Zhou, Professor G. Montalescot, Professor S. Nicholls, Doctor M. Karakas

Access

Video

About the event

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Congress

Low-dose rivaroxaban during the acute phase of ACS - H-REPLACE Trial)

About the speaker

Professor Shenghua Zhou

3 more presentations in this session

QUORUM : Quantum Genomics Firibastat (QGC001) or Ramipril after Acute Myocardial Infarction for Prevention of Left Ventricular Dysfunction

HUYGENS: Evolocumab and changes in plaque composition on OCT

ACCOST-HH: Adrecizumab in cardiogenic shock

Access the full session

Late Breaking Trials in ACS

About the event

ESC Congress 2021 - The Digital Experience

ESC 365 is supported by